EUVIMEDEUVIMED entdecken
Open Access

Single-Dose Psilocybin Treatment for Major Depressive Disorder

Charles L Raison, Gerard Sanacora, Joshua Woolley, Keith Heinzerling, Boadie W Dunlop, Randall T Brown, Rishi Kakar, Michael Hassman, Rupal P Trivedi, Reid Robison, Natalie Gukasyan, Sandeep M Nayak und 22 weitere

JAMA · 05.09.2023 · 330 (9) · 843

DOI: 10.1001/jama.2023.14530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 05.09.2023. Verfasst von Charles L Raison und 33 weiteren Autor:innen. Beteiligte Einrichtung: Usona Institute, Fitchburg, Wisconsin. Hauptthemen laut MEDLINE: Major Depressive Disorder, Hallucinogens, Niacin. Die Arbeit wurde bisher 576-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD).

Objective

To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of MDD of at least 60 days’ duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents who otherwise met inclusion/exclusion criteria were eligible following medication taper. Primary and secondary outcomes and adverse events (AEs) were assessed at baseline (conducted within 7 days before dosing) and at 2, 8, 15, 29, and 43 days after dosing.

Interventions

Interventions were a 25-mg dose of synthetic psilocybin or a 100-mg dose of niacin in identical-appearing capsules, each administered with psychological support. Main Outcomes and Measures The primary outcome was change in central rater–assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43. The key secondary outcome measure was change in MADRS score from baseline to day 8. Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 and MADRS-defined sustained response and remission. Participants, study site personnel, study sponsor, outcome assessors (raters), and statisticians were blinded to treatment assignment.

Results

A total of 104 participants (mean [SD] age, 41.1 [11.3] years; 52 [50%] women) were randomized (51 to the psilocybin group and 53 to the niacin group). Psilocybin treatment was associated with significantly reduced MADRS scores compared with niacin from baseline to day 43 (mean difference,−12.3 [95% CI, −17.5 to −7.2]; P <.001) and from baseline to day 8 (mean difference, −12.0 [95% CI, −16.6 to −7.4]; P < .001). Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, −2.31 [95% CI, −3.50 to −1.11]; P < .001) from baseline to day 43. More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin. There were no serious treatment-emergent AEs; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs. Conclusions and Relevance Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin—when administered with psychological support—may hold promise as a novel intervention for MDD. Trial Registration ClinicalTrials.gov Identifier: NCT03866174

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderHallucinogensNiacinAdultHumansFemaleMalePsilocybinMental Health

Substanzen

HallucinogensPsilocybinNiacin

Autor:innen und Institutionen

  • Usona Institute, Fitchburg, Wisconsin.
  • Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut.
  • Department of Psychiatry and Behavioral Sciences, University of California San Francisco.
  • San Francisco Veterans Affairs Medical Center, San Francisco, California.
  • Pacific Neuroscience Institute, Santa Monica, California.
  • Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O'Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., …, & Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530

Vancouver

Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA. 2023;330(9):843. doi:10.1001/jama.2023.14530

BibTeX
@article{Raison2023,
  author = {Raison, Charles L and Sanacora, Gerard and Woolley, Joshua and Heinzerling, Keith and Dunlop, Boadie W and Brown, Randall T and Kakar, Rishi and Hassman, Michael and Trivedi, Rupal P and Robison, Reid and Gukasyan, Natalie and Nayak, Sandeep M and Hu, Xiaojue and O'Donnell, Kelley C and Kelmendi, Benjamin and Sloshower, Jordan and Penn, Andrew D and Bradley, Ellen and Kelly, Daniel F and Mletzko, Tanja and Nicholas, Christopher R and Hutson, Paul R and Tarpley, Gary and Utzinger, Malynn and Lenoch, Kelsey and Warchol, Kasia and Gapasin, Theraysa and Davis, Mike C and Nelson-Douthit, Courtney and Wilson, Steffanie and Brown, Carrie and Linton, William and Ross, Stephen and Griffiths, Roland R},
  title = {Single-Dose Psilocybin Treatment for Major Depressive Disorder},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {9},
  pages = {843},
  doi = {10.1001/jama.2023.14530}
}
Kostenlos starten →